U.S. antitrust enforcers launched a flurry of initiatives in the first half of 2024 to identify and prevent antitrust and other violations in life sciences and health care. Among these are two cross-agency Requests for...more
The U.S. Department of Justice (DOJ) and Federal Trade Commission (FTC) have finalized their revamped Merger Guidelines. The 2023 iteration reflects hostility and skepticism toward M&A. Its impact on enforcement, however, is...more
This report series examines quarterly trends in life sciences venture investment. Key findings for Q3 2023 include:
Life sciences VC deal value in Q3 2023 totaled $7.7 billion, representing an uptick from last quarter...more
The Federal Trade Commission and Department of Justice Antitrust Division recently took two significant steps to overhaul merger reviews.
Proposed changes to the Merger Guidelines that would push the envelope in certain...more
This report series examines quarterly trends in life sciences venture investment. Key findings for Q4 2022 include:
• Deal value reached $7.1 billion in Q4 across 392 deals, bringing the 2022 annual total to $38.0 billion...more